Copyright
©The Author(s) 2016.
World J Cardiol. Aug 26, 2016; 8(8): 481-487
Published online Aug 26, 2016. doi: 10.4330/wjc.v8.i8.481
Published online Aug 26, 2016. doi: 10.4330/wjc.v8.i8.481
CCS | 0 | 1-100 | 101-400 | > 400 | P |
n | 154 | 198 | 165 | 134 | |
Age | 63.1 ± 11.7 | 68.2 ± 8.5 | 69.6 ± 9.8 | 71.5 ± 8.1 | < 0.0001 |
Male sex | 76 (49.4) | 137 (69.2) | 121 (73.3) | 98 (73.1) | < 0.0001 |
Risk factor | |||||
Hypertension | 85 (55.2) | 125 (63.1) | 115 (69.7) | 99 (73.9) | 0.0045 |
Dyslipidemia | 88 (57.1) | 124 (62.6) | 105 (63.4) | 82 (61.2) | 0.6484 |
Diabetes | 53 (34.4) | 76 (38.4) | 65 (39.4) | 76 (56.7) | 0.0007 |
Stroke | 36 (23.4) | 58 (29.3) | 58 (35.2) | 58 (43.3) | 0.0024 |
CKD | 30 (19.5) | 47 (23.7) | 47 (28.5) | 43 (32.1) | 0.07 |
BMI (kg/m2) | 25.7 ± 3.7 | 24.4 ± 2.6 | 24.2 ± 3.7 | 23.8 ± 4.8 | 0.2514 |
Laboratory data | |||||
HbA1c (mmol/mol) | 46.1 ± 13.4 | 47.4 ± 14.5 | 48.5 ± 13.0 | 48.9 ± 12.0 | 0.3286 |
BS (mmol/L) | 7.43 ± 2.37 | 7.73 ± 2.44 | 7.94 ± 2.39 | 8.52 ± 2.99 | 0.0333 |
TC (mmol/L) | 5.24 ± 0.99 | 5.13 ± 0.99 | 4.95 ± 0.98 | 4.72 ± 0.87 | 0.0054 |
TG (mmol/L) | 1.69 ± 1.12 | 1.63 ± 1.01 | 1.73 ± 0.94 | 1.72 ± 0.90 | 0.8925 |
HDL-C (mmol/L) | 1.50 ± 0.51 | 1.47 ± 0.43 | 1.29 ± 0.30 | 1.41 ± 0.39 | 0.0084 |
LDL-C (mmol/L) | 3.18 ± 0.86 | 2.93 ± 0.91 | 2.96 ± 0.85 | 2.68 ± 0.72 | 0.0023 |
Cr (μmol/L) | 69.0 ± 28.3 | 73.4 ± 19.4 | 75.1 ± 17.7 | 78.7 ± 21.2 | 0.0481 |
Medication | |||||
ARB/ACE-I | 70 (45.5) | 101 (51.0) | 98 (59.4) | 97 (72.4) | < 0.0001 |
CCB | 53 (34.4) | 98 (49.5) | 96 (58.2) | 95 (70.9) | < 0.0001 |
Diuretics | 5 (3.2) | 10 (5.1) | 9 (5.5) | 7 (5.2) | 0.7883 |
Beta-blocker | 3 (1.9) | 5 (2.5) | 3 (1.8) | 4 (3.0) | 0.9096 |
Aspirin | 37 (24.0) | 60 (30.3) | 61 (37.0) | 60 (44.8) | 0.0013 |
Statin | 85 (55.2) | 119 (60.1) | 100 (60.6) | 79 (59.0) | 0.7559 |
Oral diabetics | 51 (33.1) | 76 (38.4) | 65 (39.4) | 76 (56.7) | 0.0004 |
Insulin | 10 (6.5) | 15 (7.6) | 16 (9.7) | 19 (14.2) | 0.112 |
CCS | 0 | 1-100 | 101-400 | > 400 | P |
n | 154 | 198 | 165 | 134 | |
High-risk plaque | 2 (1.3)b | 20 (10.1) | 22 (13.3) | 18 (13.4) | 0.0171 |
Positive remodeling | 2 (1.3)d | 20 (10.1) | 21 (12.7) | 18 (12.7) | < 0.001 |
Low attenuation plaque | 0 (0)e | 7 (3.5) | 4 (2.4) | 1 (0.7) | 0.0217 |
Spotty calcification | 0 (0)h | 13 (6.6) | 11 (6.7) | 8 (6.0) | < 0.001 |
Napkin-ring sign | 0 (0)i | 7 (3.5) | 2 (1.2) | 1 (0.7) | 0.0474 |
Multiple plaques | 0 (0) | 4 (2.0) | 3 (1.8) | 3 (2.2) | 0.166 |
%APV | 30.5 ± 24.3 | 42.5 ± 9.0 | 44.8 ± 9.2 | 42.2 ± 7.8 | 0.2537 |
OR | 95%CI | P | |
High-risk plaque factor | |||
Male | 4.93 | 2.07-11.7 | 0.0003 |
Hypertension | 2.2 | 1.13-4.28 | 0.0204 |
Significant stenosis factor | |||
Hypertension | 2.66 | 1.44-4.89 | 0.0017 |
Dyslipidemia | 2 | 1.15-3.47 | 0.0137 |
Diabetes | 2.32 | 1.42-3.79 | 0.0008 |
High-risk CCS factor | |||
Age | 1.06 | 1.03-1.08 | 0.00001 |
Male | 1.54 | 1.02-2.34 | 0.0414 |
Diabetes | 2.46 | 1.68-3.59 | 0.0001 |
- Citation: Iwasaki K, Matsumoto T. Relationship between coronary calcium score and high-risk plaque/significant stenosis. World J Cardiol 2016; 8(8): 481-487
- URL: https://www.wjgnet.com/1949-8462/full/v8/i8/481.htm
- DOI: https://dx.doi.org/10.4330/wjc.v8.i8.481